Navigation Links
Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
Date:3/17/2011

South San Francisco, CA, March 18, 2011 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure. This publication reveals, for the first time in a peer reviewed journal, the mechanism of action for omecamtiv mecarbil and the scientific rationale for directly modulating cardiac contractility as an innovative therapeutic strategy for improving cardiac performance in patients with heart failure.

"It is our honor to have Cytokinetics' novel scientific research into direct modulators of the cardiac contractile apparatus published in this prestigious journal," stated Fady I. Malik, MD, FACC, Cytokinetics' Vice President of Biology and Therapeutics and lead author of this report. "This publication summarizes the pioneering work performed by our dedicated research team that has supported the progression of our lead compound, omecamtiv mecarbil, through clinical development and now into Phase IIb clinical trials, which will be conducted by Amgen in collaboration with Cytokinetics."

The publication titled, "Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure," discusses the potential clinical role for therapies that directly activate cardiac myosin in the treatment of systolic heart failure. The authors recognized that decreased cardiac contractility is a central feature of systolic heart failure and that there is a need for more safe and effective treatment options to improve cardiac contractility. Existing drugs that increase cardiac contractility do so indirectly through signaling cascades but their use is limited by their mechanism-related adverse effects. Omecamtiv mecarbil, a small-molecule, direct
'/>"/>

Contact: Christopher Keenan
ckeenan@cytokinetics.com
415-505-2581
Cytokinetics, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) ... in HW_Technical Insights" report to their offering. ... trends in the Health and Wellness sector and has ... an impact in the year 2015. The research service ... health and wellness technologies that are anticipated to have ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... Acquisition Expected to Add New Drug Products to Aida Pharmaceuticals, ... ... MONICA, Calif., March 27 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: ... to acquire a controlling interest,in one of the leading microbiology ...
... Pharmasset, Inc.,(Nasdaq: VRUS ), a pharmaceutical company ... treat viral infections, is,pleased to announce the appointment ... the,Board of Directors and the Nominating and Corporate ... the Board of Directors of Sapphire,Therapeutics, a Director ...
... Led by OrbiMed Advisors, World,s Largest Healthcare ... ... a,bio-pharmaceutical company developing Anticalins(R), a novel class of,targeted human protein therapeutics, ... by new investor OrbiMed Advisors LLC, a major global fund dedicated,to ...
Cached Biology Technology:Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 2Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 3Pharmasset Appoints Herbert J. Conrad as a Director 2Pharmasset Appoints Herbert J. Conrad as a Director 3Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 2Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 3Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 4
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... Palo Alto, CA Researchers at the Carnegie Institution,s ... link in the so-called signaling pathway for plant steroid ... molecules that start at the cell surface and cascade ... the first such pathway in plants for which all ...
... for many a person this is the greatest of pleasures. ... we drink beer as it is among the most energy-intensive ... (TUM) are working hard to improve the energy balance of ... combination that would allow energy savings of up to 20% ...
... periodontitis, a form of gum disease, is an independent ... This suggests the need for increased efforts to prevent ... the risk of this form of cancer. "Prevent ... maintain good oral hygiene," said Mine Tezal, D.D.S., Ph.D., ...
Cached Biology News:Plants on steroids: Key missing link discovered 2Environmentally 'green' beer: Munich brewing engineers research energy savings 2Environmentally 'green' beer: Munich brewing engineers research energy savings 3Prevent periodontitis to reduce the risk of head and neck cancer 2
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... universal lysis buffer, PCR mix, DNA polymerase ... l volume PCR reactions. This system can ... positive rod and coccus bacteria, such as ... Aureus, Streptococcus Agalactiae, and etc. With the ...
...
Biology Products: